Clinical significance of metastatic-tumor HER2 status in patients with HER2-positive primary breast cancer

被引：0
|
作者：
Niikura, N.
Liu, J.
Hayashi, N.
Mittendorf, E. A.
Gong, Y.
Palla, S. L.
Tokuda, Y.
Gonzalez-Angulo, A. M.
Hortobagyi, G. N.
Ueno, N. T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Tokai Univ, Sch Med, Kanagawa 2591100, Japan
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
545
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
    Kourie, Hampig Raphael
    Chaix, Marie
    Gombos, Andrea
    Aftimos, Phillippe
    Awada, Ahmad
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (08) : 947 - 957
  • [22] Clinical significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, in HER2-positive breast cancer
    Horii, R.
    Matsuura, M.
    Nitta, H.
    Maruyama, R.
    Ito, Y.
    Ueno, T.
    Iwase, T.
    Ohno, S.
    Akiyama, F.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S150 - S150
  • [23] Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer
    Park, Song Ee
    Park, Kyunghee
    Lee, Eunjin
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Im, Young-Hyuck
    Lee, Choonghoon
    Jung, Hun
    Cho, Soo Youn
    Park, Woong-Yang
    Cristescu, Razvan
    Park, Yeon Hee
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [24] High HER2 gene amplification and clinical outcomes in localized HER2-positive breast cancer
    Reynolds, K. L.
    Sasmit, S.
    Moy, B.
    Elena, B.
    Amy, C.
    Atul, B.
    Aditya, B.
    CANCER RESEARCH, 2013, 73
  • [25] Heterogeneous HER2 Amplification-a New Clinical Category of HER2-Positive Breast Cancer?
    Okines, Alicia F. C.
    Turner, Nicholas C.
    CANCER DISCOVERY, 2021, 11 (10) : 2369 - 2371
  • [26] Treatment of HER2-Positive Metastatic Breast Cancer
    van Ramshorst, Mette S.
    Sonke, Gabe S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1964 - 1964
  • [27] Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
    Beije, Nick
    Onstenk, Wendy
    Kraan, Jaco
    Sieuwerts, Anieta M.
    Hamberg, Paul
    Dirix, Luc Y.
    Brouwer, Anja
    de Jongh, Felix E.
    Jager, Agnes
    Seynaeve, Caroline M.
    Van, Ngoc M.
    Foekens, John A.
    Martens, John W. M.
    Sleijfer, Stefan
    NEOPLASIA, 2016, 18 (11): : 647 - 653
  • [28] Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer
    Aurilio, Gaetano
    Sandri, Maria Teresa
    Pruneri, Giancarlo
    Zorzino, Laura
    Botteri, Edoardo
    Munzone, Elisabetta
    Adamoli, Laura
    Facchi, Giuseppina
    Cullura, Daniela
    Verri, Elena
    Rocca, Maria Cossu
    Zurrida, Stefano
    Iacovelli, Roberto
    Nole, Franco
    FUTURE ONCOLOGY, 2016, 12 (17) : 2001 - 2008
  • [29] Clinical implication of HER2 status change after neoadjuvant chemotherapy with Trastuzumab and Pertuzumab (HP) in patients with HER2-positive breast cancer
    Ferraro, Emanuela
    Safonov, Anton
    Wen, Hanna Y.
    Brogi, Edi
    Gonan, Mithat
    Barrio, Andrea V.
    Razavi, Pedram
    Chandarlapaty, Sarat
    Modi, Shanu
    Seidman, Andrew D.
    Norton, Larry
    Robson, Mark E.
    Dang, Chau T.
    CANCER RESEARCH, 2022, 82 (04)
  • [30] Updates in HER2-Positive Metastatic Breast Cancer
    Gadi, V. K.
    Iyengar, Neil
    Isaacs, Claudine
    Kaklamani, Virginia
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 588 - 591
12345